Rosiglitazone: To be or not to be?

Diabetologia

Volumn 52, Issue 7, 2009, Pages 1448-1450

  Scheen, A J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ROSIGLITAZONE;

CARDIOVASCULAR RISK; CONSENSUS; DRUG SAFETY; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; PRACTICE GUIDELINES AS TOPIC; THIAZOLIDINEDIONES;

EID: 67349111808     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-009-1358-z     Document Type: Letter

References (14)

1. DM Nathan JB Buse MB Davidson 2009 Medical management of hyperglycaemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetologia 52 17 30
2. DM Nathan JB Buse MB Davidson 2006 Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetologia 49 1711 1721 (Pubitemid 44025023)
3. DM Nathan JB Buse MB Davidson 2008 Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones Diabetologia 51 8 11 (Pubitemid 50004100)
4. RM Lago PP Singh RW Nesto 2007 Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials Lancet 370 1129 1136 (Pubitemid 47464583)
5. JO Friedrich J Beyene NKJ Adhikari 2009 Rosiglitazone: can meta-analysis accurately estimate excess cardiovascular risk given the available data? Re-analysis of randomized trials using various methodologic approaches BMC Research Notes 2 5
6. D Geng D Jin W Wei 2009 Effect of thiazolidinediones on in-stent restenosis in patients after coronary stenting: a meta-analysis of randomized controlled trials Atherosclerosis 202 521 528
7. The Action to Control Cardiovascular Risk in Diabetes Study Group 2008 Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2545 2559
8. W Duckworth C Abraira T Moritz 2009 Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 360 129 139
9. Gever J (2008) ADA: VA Diabetes Trial appears to vindicate rosiglitazone (Avandia) safety. Available from http://www.medpage today.com/MeetingCoverage/ ADA/9749, accessed 1 March 2009
10. SE Kahn SM Haffner MA Heise for the ADOPT Study Group 2006 Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 355 2427 2443 (Pubitemid 44903747)
11. PD Home SJ Pocock H Beck-Nielsen 2007 Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis N Engl J Med 357 28 38 (Pubitemid 47026732)
12. AJ Scheen 2008 Exenatide once weekly in type 2 diabetes Lancet 372 1197 1198
13. MG Goldner GL Knatterud TE Prout 1971 Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results JAMA 218 1400 1410
14. D Luft RM Schmülling M Eggstein 1978 Lactic acidosis in biguanide-treated diabetics: a review of 330 cases Diabetologia 14 75 87 (Pubitemid 8277514)